Accurate fusion transcript identification from long- and short-read isoform sequencing at bulk or single-cell resolution
Open Access
- 14 March 2025
- journal article
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 35 (4) , 967-986
Abstract
Gene fusions are found as cancer drivers in diverse adult and pediatric cancers. Accurate detection of fusion transcripts is essential in cancer clinical diagnostics and prognostics and for guiding therapeutic development. Most currently available methods for fusion transcript detection are compatible with Illumina RNA-seq involving highly accurate short-read sequences. Recent advances in long-read isoform sequencing enable the detection of fusion transcripts at unprecedented resolution in bulk and single-cell samples. Here, we developed a new computational tool, CTAT-LR-Fusion, to detect fusion transcripts from long-read RNA-seq with or without companion short reads, with applications to bulk or single-cell transcriptomes. We demonstrate that CTAT-LR-Fusion exceeds the fusion detection accuracy of alternative methods as benchmarked with simulated and genuine long-read RNA-seq. Using short- and long-read RNA-seq, we further apply CTAT-LR-Fusion to bulk transcriptomes of nine tumor cell lines and to tumor single cells derived from a melanoma sample and three metastatic high-grade serous ovarian carcinoma samples. In both bulk and single-cell RNA-seq, long isoform reads yield higher sensitivity for fusion detection than short reads with notable exceptions. By combining short and long reads in CTAT-LR-Fusion, we are able to further maximize the detection of fusion splicing isoforms and fusion-expressing tumor cells.Keywords
Funding Information
- National Cancer Institute (U24CA180922)
- Marie Sklodowska-Curie (#766030)
This publication has 73 references indexed in Scilit:
- Targeted in silico characterization of fusion transcripts in tumor and normal tissues via FusionInspectorCell Reports Methods, 2023
- LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathwayHuman Cell, 2022
- Gene fusion neoantigens: Emerging targets for cancer immunotherapyCancer Letters, 2021
- LncRNA NUTM2A‐AS1 positively modulates TET1 and HIF‐1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR‐376aCancer Medicine, 2020
- EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non‐small cell lung cancerInternational Journal of Cancer, 2018
- Mechanism of ETV6-RUNX1 Leukemia2017
- The clinical implication of SS18 -SSX fusion gene in synovial sarcomaBritish Journal of Cancer, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- PAX3–FOXO1 fusion gene in rhabdomyosarcomaCancer Letters, 2008
- Scrambled exonsCell, 1991